A Phase 1 interventional study of YG-01 Dose Level 1 and YG-01 Dose Level 2 in Glioblastoma, sponsored by YGION Biomedical GmbH. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by YGION Biomedical GmbH · Phase 1, Interventional, and Treatment
Among 37 studies in Glioblastoma with a site in Austria — 7 open to participants now, 11 under way, 4 of them phase 3. Glioblastoma · Austria.
Among the 37 studies in Glioblastoma with a site in Austria, this one is the 33rd largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 37th registered.
2,134 studies on the registry are indexed under Glioblastoma; 466 are open to participants now.
Browse Glioblastoma studies →7 of the 37 studies in Glioblastoma with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in Austria, Australia, Belgium and 1 more country
Ages 18+
Vastra Gotaland Region · Sites in Austria, Denmark, Norway and 1 more country
Ages 18–70
Medical University of Vienna · Sites in Austria
Ages 18–75
European Organisation for Research and Treatment of Cancer - EORTC · Sites in Austria, Belgium, Czechia and 8 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 14
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 36 across 1,755 interventional studies indexed under Glioblastoma.
Median enrollment 120 across the 35 interventional studies, 330 across the 2 observational. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with YGION Biomedical GmbH as lead sponsor.
YGION Biomedical GmbH has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Glioblastoma with a site in Austria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07100730Phase 3Telix Pharmaceuticals (Innovations) Pty LimitedStudy of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma | 2027-07 |
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
| NCT05450744Telix Pharmaceuticals (Innovations) Pty Limited131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 37 studies in Glioblastoma with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.
Pre-Production Screening inclusion criteria:
Pre-Therapy Screening inclusion criteria:
Pre-Production Screening exclusion criteria:
Pre-Therapy Screening exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive YG-01, a personalized neoantigen immunotherapy comprising patient-specific neoepitope peptides administered subcutaneously at Dose Level 1.
Biological: YG-01 Dose Level 1
Patients receive YG-01 at Dose Level 2 subcutaneously on the same schedule as Dose Level 1, started after Safety Committee review of Dose Level 1.
Biological: YG-01 Dose Level 2
YG-01 administered subcutaneously at Dose Level 1 according to the study treatment schedule.
YG-01 administered subcutaneously at Dose Level 2 according to the study treatment schedule.
Incidence of local and systemic adverse events within 7 days following each administration of YG-01
Treatment-emergent local (injection-site) and systemic adverse events, graded by NCI CTCAE v6.0, starting within 7 days after each administration. Summarized per administration and overall, by severity, seriousness and relationship to YG-01.
Time frame: From baseline until 7 days after each YG-01 administration.
Incidence of treatment-emergent adverse events over the study period
All treatment-emergent adverse events during the treatment period, and YG-01-related adverse events during follow-up graded by NCI CTCAE v6.0.
Time frame: From baseline until study completion
Progression-free survival (PFS)
Time from study treatment start (baseline) to tumor progression on MRI or death from any cause.
Time frame: From baseline until progression or death (up to 24 months)
Overall Survival (OS)
Time from study treatment start (baseline) to death from any cause.
Time frame: From baseline until death (up to 24 months)
Induction neoantigen-specific T-cell Responses
T-cell responses against the patient-specific neoepitopes in peripheral blood, analyzed descriptively.
Time frame: From Pre-Production Screening until end of study (up to 24 months)
Induction of YG-01-specific antibody responses
Antibody responses against YG-01 in serum, analyzed descriptively.
Time frame: From Pre-Production Screening until end of study (up to 24 months)
Induction of cytokine responses
Changes in serum cytokine profiles will be assessed and analyzed descriptively.
Time frame: From Pre-Production Screening until end of study (up to 24 months)
Cytotoxicity potential of T cells
The cytotoxic activity of neoantigen-specific T cells will be assessed in vitro and analyzed descriptively.
Time frame: From Pre-Production Screening until end of study (up to 24 months)
Plan to share: No — Individual participant data will not be shared. Summary results will be posted in CTIS and on ClinicalTrials.gov.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.
Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 17 months is below that.
Counting every sponsor, half of 322 studies reached it within 44 months; a quarter within 29 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.